Authors
Latest:
Supportive Care and Medication Access in GvHDHana Safah, MD, and Corey Cutler, MD, MPH, conclude with clinical insights on addressing medication access and the supportive care needs of patients with GvHD.
Latest:
Final Thoughts: GVHDAll panelists provide their final thoughts on the current landscape and future directions in graft-vs-host disease (GVHD).
Latest:
Dr. Summers on Role of CAR T Cells in Pediatric CancerCorinne Summers, MD, pediatric oncologist, Seattle Children's Hospital, assistant member, Clinical Research Division, University of Washington Fred Hutchinson Cancer Research Center, discusses the role of CAR T cells in pediatric cancer.
Latest:
Dr. van Tilburg on Larotrectinib in TRK+ Pediatric CancersCornelis M. van Tilburg, MD, PhD, pediatric oncologist, Hopp Children’s Cancer Center Heidelberg, discusses the activity of larotrectinib (Vitrakvi) in patients with TRK fusion–positive cancers who have brain metastases or primary central nervous system tumors.
Latest:
Cory Abate-Shen on Bladder Cancer ModelingCory Abate-Shen, PhD, research faculty, Columbia Urology, Columbia University Medical Center, discusses the challenges of bladder cancer modeling.
Latest:
Dr. Lallas on Understanding Immunotherapy in GU MalignanciesCostas Lallas, MD, professor at Sidney Kimmel Medical College, Thomas Jefferson University Hospital, discusses the importance of understanding novel agents such as immunotherapeutic across disciplines in the treatment of genitourinary malignancies.
Latest:
Dr DiNardo on the FDA Approval of Ivosidenib in Relapsed/Refractory, IDH1+ MDSCourtney D. DiNardo, MD, MSCE, discusses the significance of the FDA approval of ivosidenib in patients with relapsed/refractory, IDH1-mutated myelodysplastic syndromes.
Latest:
Dr. Reeder on Future Treatment Approaches in Aggressive LymphomasCraig B. Reeder, MD, assistant professor of Medicine, Mayo Clinic, discusses some future treatment approaches for patients with aggressive lymphomas, including diffuse large B-cell lymphoma.
Latest:
Dr. Blinderman on Early Palliative Care for Patients With Metastatic DiseaseCraig Blinderman, MD, Attending Physician in Medicine & Anesthesiology NewYork-Presbyterian Hospital/Columbia University Medical Center, Assistant Professor of Palliative Care (Medicine & Anesthesiology), Columbia University, discusses starting palliative care early in patients with metastatic disease.
Latest:
Dr. Hofmeister Discusses Checkpoint Inhibitors in MyelomaCraig Hofmeister, MD, associate professor, The Ohio State University Comprehensive Cancer Center, discusses checkpoint inhibitors in multiple myeloma.
Latest:
Dr. Tendler on Breakthrough Designation for IbrutinibCraig L. Tendler, MD, Vice President, Late Development and Global Medical Affairs for Oncology, Janssen Oncology, discusses the importance of ibrutinib's Breakthrough Therapy Designation.
Latest:
Dr. Moskowitz on Antibody-Drug Conjugates in Relapsed/Refractory DLBCLCraig Moskowitz, MD, discusses the efficacy of several antibody-drug conjugates in diffuse large B-cell lymphoma, how their adverse effect profiles compare, and how bispecific antibodies are further defining the DLBCL treatment landscape.
Latest:
Dr. Sauter on the Potential Role of BTK Inhibitors in Frontline CNS LymphomaCraig Sauter, MD, discusses where BTK inhibitors could fit into the frontline treatment landscape for patients with central nervous system lymphoma and research aiming to address other unmet needs for this patient population.
Latest:
Cristi Radford on Utilizing Gene Panels in Ovarian CancerCristi Radford, MS, CGC, from the Sarasota Memorial Hospital, discusses examining cancer gene panels using next generation sequencing for patients with ovarian cancer.
Latest:
Dr. Sessa on the Management of BRCA1/2 Mutations in Ovarian CancerCristiana Sessa, MD, head of Phase I-II Unit and Pharmacology, vice head of Medical Oncology and Head of Clinical Research, Oncology Institute of Southern Switzerland, discusses the management of BRCA1/2 mutations in patients with ovarian cancer.
Latest:
Improving Care in Multiple Myeloma: Unmet Needs and Future DirectionsClosing out their discussion on novel agents in multiple myeloma, expert panelists consider remaining unmet needs and future evolutions in the treatment paradigm.
Latest:
Teclistamab in RRMM: Patient Selection and Combining TherapiesShifting toward the practical use of bispecific antibody teclistamab in RRMM, experts consider appropriate patient selection and investigational combination strategies.
Latest:
Cervical Cancer Screening Overuse and Underuse: Patient and Physician FactorsFor a decade, US medical professional organizations and the US Preventive Services Task Force have suggested that low-risk women (history of multiple normal Papanicolaou [pap] tests, age over 30 years) receive cervical cancer screening every 3 years as part of routine preventive services.
